HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) shares passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $14.70 and traded as low as $13.91. HUTCHMED shares last traded at $14.15, with a volume of 10,748 shares traded.

Analysts Set New Price Targets

HCM has been the subject of several analyst reports. Bank of America decreased their price objective on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Wall Street Zen cut HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $16.88.

HUTCHMED Stock Up 0.2%

The business has a fifty day moving average of $14.70 and a two-hundred day moving average of $14.84. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.05.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The business had revenue of $135.42 million during the quarter, compared to the consensus estimate of $290.50 million. As a group, equities research analysts expect that HUTCHMED will post 0.16 EPS for the current year.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. raised its position in HUTCHMED by 4.7% during the second quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares during the period. Bank of America Corp DE grew its position in shares of HUTCHMED by 5.9% in the third quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock valued at $343,000 after purchasing an additional 1,209 shares during the period. Crossmark Global Holdings Inc. increased its stake in shares of HUTCHMED by 3.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 52,476 shares of the company’s stock worth $700,000 after purchasing an additional 1,680 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in shares of HUTCHMED by 12.1% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,363 shares of the company’s stock worth $273,000 after purchasing an additional 1,873 shares in the last quarter. Finally, State Street Corp raised its position in shares of HUTCHMED by 1.2% during the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after purchasing an additional 3,801 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.